Attachment of stem leukemic cells to the bone marrow extracellular matrix increases their resistance to chemotherapy and contributes to the disease persistence. In chronic myelogenous leukemia (CML), the activity of the fusion BCR-ABL kinase affects adhesion signaling. Using real-time monitoring of microimpedance, we studied in detail the kinetics of interaction of human CML cells (JURL-MK1, MOLM-7) and of control BCR-ABL-negative leukemia cells (HEL, JURKAT) with fibronectin-coated surface. The effect of two clinically used kinase inhibitors, imatinib (a relatively specific c-ABL inhibitor) and dasatinib (dual ABL/SRC family kinase inhibitor), on cell binding to fibronectin is described. Both imatinib and low-dose (several nM) dasatinib reinforced CML cell interaction with fibronectin while no significant change was induced in BCR-ABL-negative cells. On the other hand, clinically relevant doses of dasatinib (100 nM) had almost no effect in CML cells. The efficiency of the inhibitors in blocking the activity of BCR-ABL and SRC-family kinases was assessed from the extent of phosphorylation at autophosphorylation sites. In both CML cell lines, SRC kinases were found to be transactivated by BCR-ABL. In the intracellular context, EC50 for BCR-ABL inhibition was in subnanomolar range for dasatinib and in submicromolar one for imatinib. EC50 for direct inhibition of LYN kinase was found to be about 20 nM for dasatinib and more than 10 µM for imatinib. Cells pretreated with 100 nM dasatinib were still able to bind to fibronectin and SRC kinases are thus not necessary for the formation of cell-matrix contacts. However, a minimal activity of SRC kinases might be required to mediate the increase in cell adhesivity induced by BCR-ABL inhibition. Indeed, active (autophosphorylated) LYN was found to localize in cell adhesive structures which were visualized using interference reflection microscopy.

Department of Cellular Biochemistry Institute of Hematology and Blood Transfusion Prague Czech Republic

Department of Cellular Biochemistry Institute of Hematology and Blood Transfusion Prague Czech Republic; Department of Cell Biology Faculty of Science Charles University Prague Prague Czech Republic

Zobrazit více v PubMed

Arai F, Hirao A, Suda T (2005) Regulation of hematopoiesis and its interaction with stem cell niches. Int J Hematol 82: 371–376. PubMed

Verfaillie CM, Hurley R, Lundell BI, Zhao C, Bhatia R (1997) Integrin-mediated regulation of hematopoiesis: Do BCR/ABL-induced defects in integrin function underlie the abnormal circulation and proliferation of CML progenitors? Acta Haematol 97: 40–52. PubMed

Wertheim JA, Forsythe K, Druker BJ, Hammer D, Boettiger D, et al. (2002) BCR-ABL-induced adhesion defects are tyrosine kinase-independent. Blood 99: 4122–4130. PubMed

Mauro MJ (2013) Striving to achieve safe, permanent treatment discontinuation in chronic myeloid leukemia. Leuk Res 37: 1395–1403. PubMed

Barnes DJ, Melo JV (2006) Primitive, quiescent and difficult to kill: The role of non-proliferating stem cells in chronic myeloid leukemia. Cell Cycle 5: 2862–2866. PubMed

Weisberg E, Azab AK, Manley PW, Kung AL, Christie AL, et al. (2012) Inhibition of CXCR4 in CML cells disrupts their interaction with the bone marrow microenvironment and sensitizes them to nilotinib. Leukemia 26: 985–990. PubMed PMC

Tsuji-Takayama K, Kamiya T, Nakamura S, Matsuo Y, Adachi T, et al. (1994) Establishment of multiple leukemia cell lines with diverse myeloid and/or megakaryoblastoid characteristics from a single Ph1 positive chronic myelogenous leukemia blood sample. Hum Cell 7: 167–171. PubMed

Martin P, Papayannopoulou T (1982) HEL cells: A new human erythroleukemia cell line with spontaneous and induced globin expression. Science 216: 1233–1235. PubMed

Kuželová K, Pluskalová M, Brodská B, Otevřelová P, Elknerová K, et al. (2010) Suberoylanilide hydroxamic acid (SAHA) at subtoxic concentrations increases the adhesivity of human leukemic cells to fibronectin. J Cell Biochem 109: 184–195. PubMed

Obr A, Röselová P, Grebeňová D, Kuželová K (2013) Real-time monitoring of hematopoietic cell interaction with fibronectin fragment: The effect of histone deacetylase inhibitors. Cell Adh Migr 7: 275–282. PubMed PMC

Grebeňová D, Röselová P, Pluskalová M, Halada P, Rösel D, et al. (2012) Proteins implicated in the increase of adhesivity induced by suberoylanilide hydroxamic acid in leukemic cells. J Proteomics 77: 406–422. PubMed

Kuželová K, Pluskalová M, Grebeňová D, Pavlásková K, Halada P, et al. (2010) Changes in cell adhesivity and cytoskeleton-related proteins during imatinib-induced apoptosis of leukemic JURL-MK1 cells. J Cell Biochem 111: 1413–1425. PubMed

Burgess MR, Skaggs BJ, Shah NP, Lee FY, Sawyers CL (2005) Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance. Proc Natl Acad Sci U S A 102: 3395–400. PubMed PMC

Manley PW, Cowan-Jacob S, Mestan J (2005) Advances in the structural biology, design and clinical development of bcr-abl kinase inhibitors for the treatment of chronic myeloid leukaemia. Biochim Biophys Acta 1754: 3–13. PubMed

Redaelli S, Piazza R, Rostagno R, Magistroni V, Perini P, et al. (2009) Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants. Journal of Clinical Oncology 27: 469–471. PubMed

O'Hare T (2005) Combined abl inhibitor therapy for minimizing drug resistance in chronic myeloid leukemia: Src/Abl inhibitors are compatible with imatinib. Clinical Cancer Research 11: 6987–6993. PubMed

Niwa T, Asaki T, Kimura S (2007) NS-187 (INNO-406), a bcr-Abl/Lyn dual tyrosine kinase inhibitor. Analytical chemistry insights 2: 93–106. PubMed PMC

Chen H, Adams E, Van Schepdael A (2013) Study of Abl1 tyrosine kinase inhibitors by liquid chromatography-electrospray ionization-mass spectrometry. Talanta 107: 88–94. PubMed

Martinelli G, Soverini S, Rosti G, Baccarani M (2005) Dual tyrosine kinase inhibitors in chronic myeloid leukemia. Leukemia 19: 1872–9. PubMed

Vainstein V, Eide CA, O'Hare T, Shukron O, Druker BJ (2013) Integrating in vitro sensitivity and dose-response slope is predictive of clinical response to ABL kinase inhibitors in chronic myeloid leukemia. Blood 122: 3331–4. PubMed PMC

Cassuto O, Dufies M, Jacquel A, Robert G (2012) All tyrosine kinase inhibitor-resistant chronic myelogenous cells are highly sensitive to ponatinib. Oncotarget 3: 1557–1565. PubMed PMC

Bradley WD, Koleske AJ (2009) Regulation of cell migration and morphogenesis by abl-family kinases: Emerging mechanisms and physiological contexts. J Cell Sci 122: 3441–3454. PubMed PMC

Bazzoni G, Carlesso N, Griffin JD, Hemler ME (1996) Bcr/Abl expression stimulates integrin function in hematopoietic cell lines. J Clin Invest 98: 521–528. PubMed PMC

Maia V, Ortiz-Rivero S, Sanz M, Gutierrez-Berzal J, Alvarez-Fernandez I, et al. (2013) C3G forms complexes with bcr-abl and p38alpha MAPK at the focal adhesions in chronic myeloid leukemia cells: Implication in the regulation of leukemic cell adhesion. Cell Commun Signal 11: 9. PubMed PMC

Salgia R, Pisick E, Sattler M, Li JL, Uemura N, et al. (1996) p130CAS forms a signaling complex with the adapter protein CRKL in hematopoietic cells transformed by the BCR/ABL oncogene. J Biol Chem 271: 25198–25203. PubMed

Salgia R, Li JL, Ewaniuk DS, Pear W, Pisick E, et al. (1997) BCR/ABL induces multiple abnormalities of cytoskeletal function. J Clin Invest 100: 46–57. PubMed PMC

Huveneers S, Danen EH (2009) Adhesion signaling - crosstalk between integrins, src and rho. J Cell Sci 122: 1059–1069. PubMed

Mitra SK, Schlaepfer DD (2006) Integrin-regulated FAK-src signaling in normal and cancer cells. Curr Opin Cell Biol 18: 516–523. PubMed

Playford MP, Schaller MD (2004) The interplay between src and integrins in normal and tumor biology. Oncogene 23: 7928–7946. PubMed

Meyn MA, Wilson MB, Abdi FA, Fahey N, Schiavone AP, et al. (2006) Src family kinases phosphorylate the bcr-abl SH3-SH2 region and modulate bcr-abl transforming activity. The Journal of biological chemistry 281: 30907–16. PubMed

Wu J, Meng F, Lu H, Kong L, Bornmann W, et al. (2008) Lyn regulates BCR-ABL and Gab2 tyrosine phosphorylation and c-cbl protein stability in imatinib-resistant chronic myelogenous leukemia cells. Blood 111: 3821–3829. PubMed PMC

Kimura S, Ashihara E, Maekawa T (2006) New tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia. Curr Pharm Biotechnol 7: 371–379. PubMed

Dubreuil P, Letard S, Ciufolini M, Gros L, Humbert M, et al. asitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT. PLoS ONE e7258. PubMed PMC

Deguchi Y, Kimura S, Ashihara E, Niwa T, Hodohara K, et al. (2008) Comparison of imatinib, dasatinib, nilotinib and INNO-406 in imatinib-resistant cell lines. Leuk Res 32: 980–983. PubMed

Nam S, Kim D, Cheng JQ, Zhang S, Lee JH, et al. (2005) Action of the src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells. Cancer Res 65: 9185–9189. PubMed

Imagawa J, Tanaka H, Matsumoto K, Morita K, Harada Y, et al. (2012) A sharp fluctuation in peripheral blood cells shortly after dasatinib administration. Int J Hematol 96: 194–199. PubMed

Scapini P, Pereira S, Zhang H, Lowell CA (2009) Multiple roles of lyn kinase in myeloid cell signaling and function. Immunol Rev 228: 23–40. PubMed PMC

Pereira S, Lowell C (2003) The lyn tyrosine kinase negatively regulates neutrophil integrin signaling. J Immunol 171: 1319–1327. PubMed

Suen PW, Ilic D, Caveggion E, Berton G, Damsky CH, et al. (1999) Impaired integrin-mediated signal transduction, altered cytoskeletal structure and reduced motility in Hck/Fgr deficient macrophages. J Cell Sci 112 (Pt 22) 4067–4078. PubMed

Mocsai A, Ligeti E, Lowell CA, Berton G (1999) Adhesion-dependent degranulation of neutrophils requires the src family kinases fgr and hck. J Immunol 162: 1120–1126. PubMed

Fumagalli L, Zhang H, Baruzzi A, Lowell CA, Berton G (2007) The src family kinases hck and fgr regulate neutrophil responses to N-formyl-methionyl-leucyl-phenylalanine. J Immunol 178: 3874–3885. PubMed PMC

Nakata Y, Tomkowicz B, Gewirtz AM, Ptasznik A (2006) Integrin inhibition through lyn-dependent cross talk from CXCR4 chemokine receptors in normal human CD34+ marrow cells. Blood 107: 4234–4239. PubMed PMC

Ingley E (2012) Functions of the lyn tyrosine kinase in health and disease. Cell Commun Signal 10: 21. PubMed PMC

Inhibition of casein kinase 2 induces cell death in tyrosine kinase inhibitor resistant chronic myelogenous leukemia cells

Adhesion structures in leukemia cells and their regulation by Src family kinases